Genomind begins depression biomarker study

Around one third of people with depression do not respond to two or more antidepressants--this is known as treatment-resistant depression--and having a blood test could help physicians determine the best possible treatment regimen for these patients and avoid the use of certain treatments in patients who are not likely to respond. An inpatient study at the Massachusetts General Hospital Department of Psychiatry has started that could validate (or not) the use of a proprietary biomarker panel in this group of patients. The study will compare standard of care with treatment guided using Genomind's Genecept Assay, and will look at improvement in depressive symptoms from baseline to 6 months, as well as changes in the clinician's choice of treatments and any changes in costs. Genomind's Genecept Assay is a combination of genetic tests targeting the serotonin transporter, glutamate, dopamine, CYP2D6 and CYP2C19, and an analytical report. Press release

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.